Catherine Hutchinson Selected Research

Heterogeneous Nuclear Ribonucleoprotein A1

1/2022	Autoimmunity to a ribonucleoprotein drives neuron loss in multiple sclerosis models.
11/2021	Knock-Down of Heterogeneous Nuclear Ribonucleoprotein A1 Results in Neurite Damage, Altered Stress Granule Biology, and Cellular Toxicity in Differentiated Neuronal Cells.
1/2020	Antibodies to the RNA binding protein heterogeneous nuclear ribonucleoprotein A1 contribute to neuronal cell loss in an animal model of multiple sclerosis.
11/2018	Dysfunctional RNA binding proteins and stress granules in multiple sclerosis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Catherine Hutchinson Research Topics

Disease

5	Multiple Sclerosis 01/2022 - 11/2018
2	Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental) 01/2022 - 01/2020
2	Neurodegenerative Diseases (Neurodegenerative Disease) 11/2021 - 11/2018
1	Amyotrophic Lateral Sclerosis (Lou Gehrig's Disease) 01/2020
1	Frontotemporal Dementia (Semantic Dementia) 01/2020

Drug/Important Bio-Agent (IBA)

4	Heterogeneous Nuclear Ribonucleoprotein A1IBA 01/2022 - 11/2018
3	RNA-Binding Proteins (RNA-Binding Protein)IBA 01/2020 - 11/2018
2	RibonucleoproteinsIBA 01/2022 - 03/2021
2	AntibodiesIBA 01/2022 - 01/2020
2	Proteins (Proteins, Gene)FDA Link 03/2021 - 11/2018
1	Immunodominant EpitopesIBA 01/2022
1	Immunoglobulin G (IgG)IBA 01/2022
1	CryptochromesIBA 03/2021
1	RNA (Ribonucleic Acid)IBA 01/2020

Therapy/Procedure

1	Therapeutics 03/2021